• Regulatory NewsRegulatory News

    European Regulatory Roundup: AstraZeneca Pulls Cancer Drug After Disagreement With EMA (29 September 2016)

    Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news. ‘Differences of Opinion’ with EMA Prompt AstraZeneca to Pull Cancer Drug Filing AstraZeneca has withdrawn its EMA marketing authorization application for cediranib in a subset of ovarian cancer patients. The company took the action after running into “differences of opinion” with EMA about the side effects of the drug and the way the study was run, The Telegraph repor...